 I-Mab NASDAQ: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, and Genexine Inc. KOSDAQ: 095700, a clinical-stage biotechnology company focused on developing innovative immunotherapeutics and novel long-acting biologics, today announced that the China National Medical Products Administration NMPA has cleared the initiation of a Phase 2 clinical trial of TJ107HyLeukin-7TM Efineptakin alfa, the novel long-acting recombinant human interleukin-7 rhIL-7, in lymphopenic patients with newly-diagnosed glioblastoma multiforme GBM. In addition, the two companies expanded their collaboration beyond the initial agreement to include development of TJ107HyLeukin-7TM for this indication. 